Early October, Thibault Leray presented his PhD work on a novel TCR-T cell product for safe and enhanced responses against melanoma at the Innovative Therapies Days in Besancon. This project was awarded Best Short Talk and reward a collective effort of the teams at the Translational Research Unit and INCIT in Nantes !
Congratulations and more to come soon on this project !
Thibault in Action (credit: organisation committee)
Ny kreftvaksine utviklet på Radiumhospitalet – Pseudovaxstudien startet inklusjon i november 2025
Some fresh news about Pseudovax study (In Norwegian)
Forskningsmiljøet ved Radiumhospitalet har utviklet en ny, persontilpasset kreftvaksine for pasienter med en sjelden og alvorlig kreftform: pseudomyxoma peritonei (PMP) – kreft i blindtarmen med spredning til bukhinnen.
June 25th 2026:
Congratulations to Henrik who successfully defended his Master thesis today!
We are grateful to UiO and to the opponents (Prof. Marit Inngjerdingen, Prof. Cinzia Progida, and Dr. Rasmus Iversen), who gave him a proper roasting 😉
Institute for Cancer Research, Seminar room 1, K-building
Save the date!
We organize the EuSARC meeting 04-06 June 2026
Don't miss the next CellFit Seminar
PROGRAM (program with additional speakers will be released by August 15, 2025)
Welcome by Moderators & Co-Chairs
Else Marit Inderberg, PhD, Unit Leader, Translational Research Unit, Section for Cell Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway
Development of CAR-Treg therapies to modulate immune responses in transplantation and autoimmunity Nathalie Belmonte, PhD, Senior VP Research and Technical Development, Quell Therapeutics
Solving CAR-T Manufacturing and QC Challenges with Structured Support and Strategic Solutions Anna Pasetto, PhD, Associate Professor, Director of Center for Advanced Cell Therapy (ACT), Oslo University Hospital, Norway
Automated manufacturing of CAR effector cells: From viral to non-viral gene transfer Ulrike Kohl, MD, PhD, Institute Director / University Professor, Institute of Clinical Immunology, Medical Faculty, University of Leipzig and Fraunhofer Institute for Cell Therapy and Immunology, Germany.
Maximizing the Innate Power of NK cells in cancer therapy Ebba Sohlberg, PhD, Researcher and Project Manager at the Center for Infectious Medicine, Karolinska Institutet, Sweden
Additional speakers will be confirmed and updated here.
NOTE about a workshop the next day:
On October 9, 2025, 9am-5pm at OCC Innovation Park: You are invited to register your interest to join a specialized workshop conducted by Thermo Fisher Scientific. Please register your interest with corinna.pohl@thermofisher.com, who will contact you early Q3 2025 about the program.
The research team millésime 2025
Christopher Forcados will defend his thesis on Tuesday 8th of April!
We are happy to annunce that Christopher Forcaods who has been at the unit for 4 years will noon defend his thesis to obtain the degree of Philosophiae Doctor (PhD) deliver by the Medical Faculty of the University of Oslo.
(The hero in action 2 years ago)
You can either come to this address: Auditorium Nye RAD L1 (U1), Bygg L, Radiumhospitalet, Ullernchausseen 70
Or follow him online:
10:15 AM Trial Lecture: “Ideas and solutions for in vivo generation of chimeric antigen receptor T cells”
Mensali N, Joaquina S, de Montlaur C, Casey NP, Nesset TO, Myklebost O, McCormack E, Pasetto A, Gunnes MW, Gelebart P, Inderberg EM, Wälchli S(2026) Pre-clinical validation of OSCAR-3 mRNA-based CAR T cells for targeting osteosarcomas Cytotherapy, 28(12), 102930 DOI 10.1016/j.jcyt.2026.102930, PubMed 42854615
Forcados C, Köksal H, Scherer E, Abrantes R, Dillard P, Duarte HO, Josefsson S, Gomes C, de Montlaur C, Hellesøy HTZ, Dunkel R, Smeland EB, Myklebust JH, Reis CA, McCormack E, Gelebart P, Inderberg EM, Wälchli S(2026) Reviving low-affinity glycan-targeting CAR with combinatorial design Cell Rep Med, 7(10), 103108 DOI 10.1016/j.xcrm.2026.103108, PubMed 42849448
Villatoro A, Dougé A, Krpina K, Schmitz LM, Forcados C, Kaveh F, Arias-Díaz AE, Gelebart P, McCormack E, Stripecke R, Abal M, Davidson B, Inderberg EM, Wälchli S(2026) Combining TAG-72CAR with anti-MUC16CAR improves the potency of ovarian cancer treatment FEBS J(in press) DOI 10.1111/febs.70760, PubMed 42834815